Beiträge zum Schlagwort:

immunotherapy

Immuno-Oncology

The role of immunotherapy for patients with rare mutations

The role of immunotherapy for patients with uncommon EGFR mutations, ROS1 and C-MET who express PD-L1 is still unclear.

ESMO 2017 Immuno-Oncology

Bladder Cancer - Mature results favour pembrolizumab as second-line treatment

Results from the KEYNOTE-045 trial have confirmed longer survival in patients with advanced urothelial cancer who receive pembrolizumab.

ESMO 2017 Immuno-Oncology

PACIFIC: Durvalumab profoundly improves progression-free survival in stage III lung cancer

Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage III lung cancer, according to late-breaking results from the phase III PACIFIC trial presented today at the ESMO 2017 Congress in Madrid